Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q13586: Variant p.His109Asn

Stromal interaction molecule 1
Gene: STIM1
Feedback?
Variant information Variant position: help 109 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Histidine (H) to Asparagine (N) at position 109 (H109N, p.His109Asn). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and polar. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In TAM1; myoblasts with the mutation have significantly increased clustering of STIM1, regardless of calcium levels, indicating that calcium sensing in the sarcoplasmic reticulum is impaired. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 109 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 685 The length of the canonical sequence.
Location on the sequence: help DEFLREDLNYHDPTVKHSTF H GEDKLISVEDLWKAWKSSEV The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         DEFLREDLNYH--DPTVKHSTFHGEDKLISVEDLWKAWKSSEV

Mouse                         DEFLREDLNYH--DPTVKHSTFHGEDKLISVEDLWKAWKSS

Rat                           DEFLREDLNYH--DPTVKHSTFHGEDKLISVEDLWKAWKAS

Bovine                        DEFLREDLNYH--DPTVKHSTFHGEDKLISVEDLWKAWKSS

Caenorhabditis elegans        TGFMKEDMQMRGSERTRRENKFHGDDDAITVDDLWEAWFES
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 23 – 685 Stromal interaction molecule 1
Topological domain 23 – 213 Extracellular
Domain 102 – 126 EF-hand 2
Mutagenesis 108 – 108 F -> D. Constitutive localization in punctae at the cell membrane and constitutive activation of CRAC channels; when associated with D-110.
Mutagenesis 110 – 110 G -> D. Constitutive localization in punctae at the cell membrane and constitutive activation of CRAC channels; when associated with D-108.



Literature citations
Constitutive activation of the calcium sensor STIM1 causes tubular-aggregate myopathy.
Boehm J.; Chevessier F.; Maues De Paula A.; Koch C.; Attarian S.; Feger C.; Hantai D.; Laforet P.; Ghorab K.; Vallat J.M.; Fardeau M.; Figarella-Branger D.; Pouget J.; Romero N.B.; Koch M.; Ebel C.; Levy N.; Krahn M.; Eymard B.; Bartoli M.; Laporte J.;
Am. J. Hum. Genet. 92:271-278(2013)
Cited for: VARIANTS TAM1 GLN-72; GLY-84; ARG-109 AND ASN-109; CHARACTERIZATION OF VARIANTS TAM1 GLN-72; GLY-84; ARG-109 AND ASN-109; Clinical, histological and genetic characterisation of patients with tubular aggregate myopathy caused by mutations in STIM1.
Boehm J.; Chevessier F.; Koch C.; Peche G.A.; Mora M.; Morandi L.; Pasanisi B.; Moroni I.; Tasca G.; Fattori F.; Ricci E.; Penisson-Besnier I.; Nadaj-Pakleza A.; Fardeau M.; Joshi P.R.; Deschauer M.; Romero N.B.; Eymard B.; Laporte J.;
J. Med. Genet. 51:824-833(2014)
Cited for: VARIANTS TAM1 THR-80; VAL-96; ILE-108; LEU-108 AND ASN-109; CHARACTERIZATION OF VARIANTS TAM1 THR-80; VAL-96; ILE-108; LEU-108 AND ASN-109; FUNCTION; SUBCELLULAR LOCATION;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.